Showing 6491-6500 of 9765 results for "".
- Baby Skincare Data at American Academy of Pediatricshttps://practicaldermatology.com/news/baby-skincare-data-american-academy-pediatrics/2468324/Kenvue Inc. will present new data demonstrating effective sleep and skin moisturization strategies for babies during the American Academy of Pediatrics (AAP) National Conference & Exhibition, set for September 27 through October 1 in Orlando, Florida. In addition to findings supporting
- Report: Nonsurgical Aesthetics Revenues Up 9%https://practicaldermatology.com/news/report-nonsurgical-aesthetics-revenues-9/2468303/Data and analytics solutions provider Guidepoint Qsight and investment banking and management consulting firm Skytale Group released a new report on the state of the aesthetics industry, highlighting the continued expansion of the US market. Combined nonsurgical revenues increased by 9% in
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat
- Frontier Acquires Mohs Specialist Doherty Dermatologyhttps://practicaldermatology.com/news/frontier-acquires-mohs-specialist-doherty-dermatology/2468264/Frontier Dermatology announced the acquisition of Doherty Dermatology, a clinic in Bellingham, Washington, that specializes in Mohs micrographic surgery. Doherty Dermatology will be rebranded as Frontier Dermatology (Bellingham South) starting October 1, joining the company's 35 other physician o
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Bimekizumab-bkzx Approved for PsA, nr-axSpA, AShttps://practicaldermatology.com/news/bimekizumab-bkzx-approved-psa-nr-axspa/2468260/Bimekizumab-bkzx has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondyl
- INTEGUMENT Trials: Once-Daily Roflumilast Cream Reduces AD Symptomshttps://practicaldermatology.com/news/integument-trials-once-daily-roflumilast-cream-reduces-ad-symptoms/2468245/Roflumilast cream, 0.15%, significantly improved symptoms of mild to moderate atopic dermatitis (AD) in two phase 3 clinical trials. Researchers for the INTEGUMENT-1 and INTEGUMENT-2, publishing their results in JAMA Dermatology, evaluated the efficacy and safety of roflumilast cr
- Study Links Psoriasis to NMSC in Womenhttps://practicaldermatology.com/news/study-links-psoriasis-nmsc-women/2468243/Psoriasis was associated with a higher risk of nonmelanoma skin cancer in women in a new study published in Nature Communications. “An observational and genetic investigation into the association between psoriasis and risk of malignancy” found higher risks of a total of 16 types of cancer
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen